
Cardinal Health (CAH) Stock Forecast & Price Target
Cardinal Health (CAH) Analyst Ratings
Bulls say
Cardinal Health is expected to experience steady growth in key metrics such as free cash flow and adjusted EPS, driven by its diversified portfolio and strong balance sheet. Despite recent challenges, the company is well-positioned for future growth in precision medicine and radiopharmaceuticals, and continues to invest in expanding capacity in these markets. With a commitment to returning capital to shareholders, Cardinal Health is a solid investment option for those with a positive outlook on the healthcare industry.
Bears say
Cardinal Health is a leading pharmaceutical distributor with a significant market share in the US, generating over 90% of its revenue from the distribution of branded, generic, and specialty pharmaceuticals. However, with a changing healthcare landscape, including increased competition and potential changes in drug pricing regulations, Cardinal Health's profitability and cash flow could be adversely impacted. Additionally, their focus on the home health space may not provide sufficient growth opportunities to offset potential headwinds in their core pharmaceutical distribution business. The recent global medical products and distribution turnaround has shown improvement, but the company faces risks related to their exposure to energy and commodity cost fluctuations as well as potential challenges in their generic and biosimilar businesses.
This aggregate rating is based on analysts' research of Cardinal Health and is not a guaranteed prediction by Public.com or investment advice.
Cardinal Health (CAH) Analyst Forecast & Price Prediction
Start investing in Cardinal Health (CAH)
Order type
Buy in
Order amount
Est. shares
0 shares